Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
Francesco Di Pierro(University of Insubria), Saeed Khan(Dow University of Health Sciences), Giuseppe Derosa(University of Pavia), Antonella Riva(Indena (Italy)), Mohsin Masud(King Edward Medical University), Amjad Khan(University of Michigan–Ann Arbor), Somia Iqtadar(King Edward Medical University), Pietro Allegrini(Indena (Italy)), Sami Ullah Mumtaz(King Edward Medical University), Pamela Maffioli(University of Pavia), Alexander Bertuccioli(University of Urbino), Stefano Togni(Indena (Italy))
Cited by 177
Related Papers
The Battle of the Water Sensor Networks (BWSN): A Design Challenge for Engineers and Algorithms
|Journal of Water Resources Planning and Management|2008|583
A role for quercetin in coronavirus disease 2019 (COVID‐19)
|Phytotherapy Research|2020|299
An Investigation on Preference Order Ranking Scheme for Multiobjective Evolutionary Optimization
|IEEE Transactions on Evolutionary Computation|2007|283
Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study
|International Journal of General Medicine|2021|183